Breaks Categories: News

ThursdayJul 21, 2022 11:26 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reports on First Full-Year Revenue, Issues KWC Status Update

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released an update on its both its financial and corporate status. According to the announcement, the company released its first end-of-year earnings report in May, which showed $1.5 million annual revenue and a growth in net assets from $2.1 million in 2020 to $10 million by 2021 year end, a 500% year-over-year increase. In addition, the company’s Ketamine Wellness Centers (“KWC”) are reporting impressive growth, offering an estimated 100,000 treatments so far at its 13 operational, state-of-the-art clinics; the company…

Continue Reading

WednesdayJul 20, 2022 12:40 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience…

Continue Reading

WednesdayJul 13, 2022 2:30 pm

PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Lucid Psycheceuticals Files for Patent on Novel Formulations of Palmitoylethanolamide

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that is wholly owned subsidiary, Lucid Psycheceuticals Inc., filed a provisional patent application on novel formulations of palmitoylethanolamide (“PEA”). According to the update, the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma. The company is diligently pursuing the clinical development of FSD201 for various indications. FSD Pharma recently announced the submission of an Investigational New Drug…

Continue Reading

TuesdayJul 12, 2022 4:44 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity,” said Eric Weisblum, CEO of Silo Pharma. “In our previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and four hours was an optimal time point…

Continue Reading

TuesdayJul 12, 2022 3:22 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment

Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the first novel psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). “Clinilabs is honored to be working with Cybin, an innovator in the development of novel psychedelic therapeutics, to conduct its first-in-human clinical trial of CYB003,” said…

Continue Reading

MondayJul 11, 2022 11:43 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1). The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1…

Continue Reading

ThursdayJun 30, 2022 1:01 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Launches Ketamine Wellness Integrative Therapist Directory

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today officially launched the Ketamine Wellness Integrative Therapist Directory. According to the update, the comprehensive resource will connect KWC patients with qualified mental health practitioners who can help them process and integrate the benefits of ketamine therapy into their everyday life. “Ketamine therapy is a rapidly growing medical field demonstrating promising results, but many patients overlook the importance of continuous cognitive therapy after their ketamine treatments to maximize the outcomes,” said Kevin Nicholson, CEO of KWC…

Continue Reading

TuesdayJun 28, 2022 12:45 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an estimated 37,366.2 class B common shares in Cybin will be issued to Adelia shareholders; the issuance of the shares represents the approximately $217,465 that Cybin agreed to pay if the key milestone was achieved. Adelia…

Continue Reading

MondayJun 27, 2022 1:49 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has received approval from the U.S. Food and Drug Administration (“FDA”) to proceed with its phase 1/2a first-in-human clinical trial evaluating CYB003; the company has received a “may proceed” letter and investigational new drug application (“IND”) clearance from the FDA. The approval means that CYB003 will be the first  novel psilocybin analog to enter clinical development, with patient recruitment beginning immediately and pharmacokinetic and safety data readout anticipated by fourth quarter 2022. According to the announcement, Cybin’s CYB003 is a proprietary deuterated psilocybin analog being developed for…

Continue Reading

ThursdayJun 23, 2022 2:54 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has expanded its commercial evaluation license agreement (“CELA”) with the University of Maryland Baltimore (“UMB”) for its next-generation liposomal peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model,” said Eric Weisblum, CEO of Silo Pharma. “To test the therapeutic effect of the peptides, arthritic…

Continue Reading